Background/Aims: In the treat-to-target era, psoriasis disease activity measures that can be easily performed in routine clinical practice are needed. This retrospective pooled analysis explored cutoff values of the product of the 5-point Investigator's Global Assessment and percentage of affected body surface area (IGA × BSA) correlating with achievement of minimal disease activity (MDA). Methods: Post hoc analysis of the phase 3 clinical trials ERASURE, FIXTURE, FEATURE, and JUNCTURE was conducted to determine associations between IGA × BSA and 2 MDA definitions (Psoriasis Area and Severity Index [PASI] 90 and Dermatology Life Quality Index [DLQI] 0/1, or PASI score ≤1 or BSA < 3%) in patients with moderate-to-severe psoriasis receiving secukinumab 300 mg. For each definition of MDA, a range of possible cutoff values of IGA × BSA was examined at each time point. The optimal cutoff value was determined using Youden index (YI), calculated as (sensitivity + specificity -1). Results: For MDA defined as PASI 90 and DLQI 0/1, optimal IGA × BSA cutoffs were 2.10 at week 12 (YI, 0.60; sensitivity, 0.78; specificity, 0.82), 1.02 at week 24 (YI, 0.55; sensitivity, 0.73; specificity, 0.82), and 1.00 at week 52 (YI, 0.65; sensitivity, 0.79; specificity, 0.86). For MDA defined as PASI score ≤1 or BSA < 3%, optimal IGA × BSA cutoffs were 2.98 at week 12 (YI, 0.91; sensitivity, 0.99; specificity, 0.92), 2.80 at week 24 (YI, 0.94; sensitivity, 0.99; specificity, 0.95), and 3.00 at week 52 (YI, 0.96; sensitivity, 1.00; specificity, 0.96). Conclusion: IGA × BSA could be a valid measure highly associated with achievement of MDA.
Introduction
Psoriasis is a common, systemic, chronic immune-mediated disease that manifests mainly as plaque, but other manifestations include guttate, flexural, erythrodermic, pustular, palmoplantar, and/or nail psoriasis [1, 2] . The goal of treatment in patients with psoriasis is to clear skin and normalize health-related quality of life, with the target of achieving minimal disease activity (MDA). Physicians and payers want a treatment target that will be used to make decisions regarding continuing, stopping, or changing treatment [3] . Currently ments, including topical agents, phototherapy, systemic therapies, and/or biologic therapies are used clinically for psoriasis [4] . The National Psoriasis Foundation guidelines for management of psoriasis recommend a treat-totarget strategy for clinicians and patients to work together to improve treatment decisions, reduce disease burden, and improve clinical outcomes [5] .
The Psoriasis Area and Severity Index (PASI) is typically used as a measure of psoriasis disease activity in clinical trials but may not be practical for use in clinical practice. Limitations of the PASI include (1) the need for complex calculations; (2) time-consuming documentation; (3) complex scoring that may not be understood by most clinicians; and (4) non-reader-friendly format due to nonlinearity, with poor sensitivity to change and poor discrimination at lower score ranges [6, 7] . Alternatively, the 5-point Investigator's Global Assessment (IGA) and percentage of affected body surface area (BSA) are measures of psoriasis disease activity that are easily performed in routine clinical practice. Valid but simple, highly feasible measures, such as the product of the 5-point IGA or Physician's Global Assessment (PGA) and percentage of affected BSA (IGA × BSA or PGA × BSA, respectively), are easily captured by health-care providers and understood by providers, regulators, and payers.
PGA × BSA has been validated and used in several studies [7] [8] [9] [10] [11] [12] ; most notably, PGA × BSA was highly correlated with PASI [7] . Furthermore, correlations between static PGA × BSA and PASI were stronger than that between BSA and PASI [13] . PGA × BSA also provided a clinically relevant assessment of MDA in patients with psoriasis, using PASI and Dermatology Life Quality Index (DLQI) response categories as anchors [14, 15] .
The simplicity of IGA × BSA or PGA × BSA may allow for their potential use in a number of novel applications, such as defining a useful minimal disease criterion for treat-to-target strategies. The focus of this study is on the 5-point IGA and its product with BSA [16] [17] [18] that correlates with defined MDA, using data from four phase 3 clinical trials of secukinumab in patients with moderateto-severe psoriasis.
Materials and Methods
For further details, see the online supplementary material (see www.karger.com/doi/10.1159/000499925 for all online suppl. material) (Fig. 1) .
Results

Pooled Baseline Characteristics
A total of 691 patients randomized to receive secukinumab 300 mg were included in the pooled pa- Table 2 ; online suppl. Fig. 1 ).
Furthermore, with the MDA definition of PASI score ≤1 or BSA < 3%, the IGA × BSA cutoff with the best sensitivity and specificity was 2.98 at week 12 (YI, 0.91; sensitivity, 0.99; specificity, 0.92), 2.80 at week 24 (YI, 0.94; sensitivity, 0.99; specificity, 0.95), and 3.00 at week 52 (YI, 0.96; sensitivity, 1.00; specificity, 0.96) ( Table 3 ; online suppl. Fig. 2 ). 
Discussion
This post hoc analysis of four phase 3 clinical trials in patients with moderate-to-severe psoriasis receiving secukinumab 300 mg showed that an IGA × BSA cutoff of 2.10-2.98 at week 12 could be a valid measure highly associated with achievement of MDA. A lower cutoff value may be needed for evaluations up to week 52 (range, 1.00-3.00), but values were mostly within the ranges reported for week 12. These results are comparable to the PGA × BSA banding of 0.0-3.0 that correlated with achievement of MDA defined as PASI ≥90 and DLQI 0/1 [14] . This further indicates the validity of IGA × BSA as a composite tool for assessing clinical response to treatment.
The treat-to-target approach has become the recommended strategy for the treatment of patients with psoriasis. New National Psoriasis Foundation guidelines for the treatment of psoriasis state that the initial treatment goal should be to reduce BSA to ≤1% after 3 months; however, a reduction in BSA to ≤3% is considered an acceptable response [5] . Calculating the optimal IGA × BSA cutoff (2.98) at week 12 on the basis of BSA < 3% aligns with the treat-to-target goal. Nevertheless, a more meaningful assessment of MDA that coincides with clinical trial endpoints in patients with moderate-to-severe psoriasis is needed in routine clinical practice and could also be a clinically relevant measure for database analyses. IGA × BSA is strongly correlated with absolute PASI score, providing further support that IGA × BSA captures disease severity and could be used to evaluate treatment response in place of the PASI. Furthermore, IGA × BSA cutoff values associated with MDA measures of PASI 90 and DLQI 0/1 include health-care provider-and patient-reported outcomes that allow patients and providers to be partners in their treat-to-target strategies, while also providing insight into patient quality of life as affected by skin clarity.
The IGA/PGA is categorized into 2 distinct basic forms: a static form, which measures the physician's evaluation of the disease activity at a single point, and a dynamic form, in which the physician assesses the global improvement from the baseline disease activity [19] . The US Food and Drug Administration prefers static IGA/ PGA; thus, clinical research generally uses static IGA/ PGA instruments. However, multiple versions of the static IGA/PGA exist, ranging from a 4-point to an 11-point scale, with varying descriptions of each point value [20, 21] . The static 5-point IGA scale, which was modified from the 6-point IGA/PGA scale [22] , has become the standard form used in many phase 3 clinical trials [16] [17] [18] . Notably, the IGA/PGA does not account for the extent of disease. Therefore, IGA × BSA can aid physicians in the evaluation of treatment responses and assessments of therapeutic options to optimize patient care.
Limitations
Despite several strengths, this study has a few limitations, mainly related to the nature of the analysis. This was a post hoc analysis using pooled trial data, the use of which was not prespecified in the protocol of the individual studies. Furthermore, no adjustments for any potential confounding variables were conducted using multivariate analyses. Currently, there is no agreed-upon standard IGA/PGA to be used for clinical assessment of disease activity; the 5-and 6-point forms commonly used in clinical trials have different definitions of each scale value, complicating the physician's ability to efficiently and consistently measure treat-to-target goals. Including patients treated with the highly effective biologic agent secukinumab in this study leaves the potential for underestimation of cutoff values when evaluating the efficacy of other therapies; this measure needs to be tested in studies that include other psoriasis treatments. As IGA × BSA was validated as an indication of MDA achievement only for patients with moderate-to-severe psoriasis, further examination of the criteria is needed for patients with all levels of psoriasis severity.
Conclusion
This exploratory post hoc analysis identified IGA × BSA as a potential simple tool to assess achievement of MDA as a treat-to-target goal; however, additional observational studies with other psoriasis treatments are needed to further investigate this measure. For example, studies examining and comparing the cutoff values for other psoriasis treatments to identify treatment targets should be conducted to provide information that may be used by physicians for making proper formulary decisions. Findings from this study may provide physicians with a more practical way to capture disease activity in routine clinical practice beyond the traditional PASI.
Key Message
IGA × BSA may provide clinicians with a simple tool to measure treat-to-target goals.
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